ITRM
NASDAQIterum Therapeutics plc
Iterum Therapeutics plc (ITRM) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. There were no new wire items for ITRM in the last 30 days. The most recent was published Mar 31, 2026.
Price$0.03-0.28 (-89.83%)
2025-12-242026-03-31
Latest news
25 items- SECIterum Therapeutics plc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events8-K - Iterum Therapeutics plc (0001659323) (Filer)
- PRIterum Therapeutics Announces Filing of Winding Up PetitionDUBLIN and CHICAGO, March 27, 2026 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (in Provisional Liquidation) (NASDAQ:ITRM) (the "Company" or "Iterum" or "we"), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has filed a petition in the High Court in Ireland to wind up the Company. An Order was made appointing Damien Murran and Jennifer McMahon, each of Teneo Restructuring (Ireland) Limited (the "Joint Provisional Liquidators"), as Joint Provisional Liquidators to the Company. The petition is due to be heard on April 13, 2026. If a winding up
- SECIterum Therapeutics plc filed SEC Form 8-K: Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Iterum Therapeutics plc (0001659323) (Filer)
- SECIterum Therapeutics plc filed SEC Form 8-K: Other Events8-K - Iterum Therapeutics plc (0001659323) (Filer)
- SECIterum Therapeutics plc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Iterum Therapeutics plc (0001659323) (Filer)
- SECIterum Therapeutics plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events8-K - Iterum Therapeutics plc (0001659323) (Filer)
- SECSEC Form DEFA14A filed by Iterum Therapeutics plcDEFA14A - Iterum Therapeutics plc (0001659323) (Filer)
- PRIterum Therapeutics Provides Business Update--Expanded Market Access and Patent Protection for ORLYNVAH™ --FDA correspondence regarding the use of ORLYNVAH™ as step-down therapy DUBLIN and CHICAGO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company" or "Iterum" or "we"), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today provided a business update. Recent Events Market Access Update: Medicare Part D Milestone: We are pleased to announce another signed rebate agreement with one of the top three Medicare Part D Pharmacy Benefit Managers, in addition to our existing agr
- SECSEC Form DEFA14A filed by Iterum Therapeutics plcDEFA14A - Iterum Therapeutics plc (0001659323) (Filer)
- SECSEC Form DEF 14A filed by Iterum Therapeutics plcDEF 14A - Iterum Therapeutics plc (0001659323) (Filer)
- SECSEC Form PRE 14A filed by Iterum Therapeutics plcPRE 14A - Iterum Therapeutics plc (0001659323) (Filer)
- PRIterum Therapeutics Provides Business UpdateDUBLIN and CHICAGO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company" or "Iterum" or "we"), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today provided a business update. Recent Events Market Access Update: Payor Reimbursement and Contracting Expands with Major PBM Agreement: ORLYNVAH™'s market access continues to accelerate. We have finalized a commercial contract with a Group Purchasing Organization that collaborates with manufacturers on behalf of one of the largest Pharmacy Benefit Managers ("PBMs") in the United States,
- SECIterum Therapeutics plc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Iterum Therapeutics plc (0001659323) (Filer)
- PRIterum Therapeutics Provides Business UpdateDUBLIN and CHICAGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company" or "Iterum" or "we"), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today provided a business update. Recent Events Market Access Update: Expanding Reimbursement Footprint: ORLYNVAH™'s access continues to grow—both with and without prior authorization or medical exception pathways, allowing coverage approval for many of the ORLYNVAH™ prescriptions written to date. Current coverage now reaches nearly 25% of insured lives in the U.S., with increasing adoption
- PRIterum Therapeutics Provides Business UpdateDUBLIN, Ireland and CHICAGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company" or "Iterum"), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today provided a business update. Recent Events Specialty Distributor Now Stocked: ORLYNVAH™ is now available at McKesson, which will allow certain physicians the ability to procure the product directly from McKesson through this specialty distribution channel, consistent with their practice preferences.Sulopenem Susceptibility Disc FDA Cleared & Now Available to Order: Iterum has received
- INSIDERDirector Dunne Michael W. bought $2,191 worth of Ordinary Shares (6,000 units at $0.37), increasing direct ownership by 3% to 241,001 units (SEC Form 4)4 - Iterum Therapeutics plc (0001659323) (Issuer)
- SECSEC Form 10-Q filed by Iterum Therapeutics plc10-Q - Iterum Therapeutics plc (0001659323) (Filer)
- SECIterum Therapeutics plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Iterum Therapeutics plc (0001659323) (Filer)
- PRIterum Therapeutics Reports Third Quarter 2025 Financial Results--Commercially Launched ORLYNVAH™ in the United States in August 2025-- --Extended Cash Runway into Q2 2026-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the Company or Iterum), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the quarter ended September 30, 2025. "We are thrilled to have launched ORLYNVAH™ in the United States in August 2025 for the treatment of uncomplicated urinary tract infections (uUTIs)," said
- PRIterum Therapeutics to Report Third Quarter 2025 Financial Results on Friday, November 14, 2025DUBLIN, Ireland and CHICAGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its third quarter 2025 financial results before the open of the U.S. financial markets on Friday, November 14, 2025. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company's financial results and provide an update on its business. To access the call please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to Ac
- SECSEC Form 8-K filed by Iterum Therapeutics plc8-K - Iterum Therapeutics plc (0001659323) (Filer)
- SECSEC Form 424B5 filed by Iterum Therapeutics plc424B5 - Iterum Therapeutics plc (0001659323) (Filer)
- PRIterum Therapeutics to Present Data at IDWeek 2025DUBLIN and CHICAGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that two posters will be presented at the Infectious Disease Society of America's IDWeek 2025 conference taking place in Atlanta, GA from October 19-22, 2025. The Company will also be conducting a Learning Lounge at IDWeek 2025 on Tuesday, October 21, 2025, 1:15 pm EST. The title of the presentation is ‘An Overview of Urinary Tract Infection in Adult Women: Focus on Oral Sulopenem.' Presenters: St
- PRIterum Therapeutics Provides Business UpdateDUBLIN and CHICAGO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (Iterum), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today provided a general business update. ORLYNVAHTM Launch Update In partnership with EVERSANA Life Science Services, LLC ("EVERSANA"), ORLYNVAH™ was launched in August 2025 into the community market in the U.S. in targeted territories across seven states.Sales representatives, contracted by and dedicated to Iterum via EVERSANA, have been actively engaging with target physicians who have shown interest in learnin
- SECIterum Therapeutics plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Iterum Therapeutics plc (0001659323) (Filer)
ITRM FAQ
8 questionsWhat does Iterum Therapeutics plc do?
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was founded in 2015 and is headquartered in Dublin, Ireland.What is the latest news on ITRM?
Quantisnow has not tracked any new filings, ratings or press releases for ITRM in the last 30 days. The most recent wire item was published on March 31, 2026.Where does ITRM stock trade?
Iterum Therapeutics plc (ITRM) is listed on NASDAQ.What sector and industry is ITRM in?
Iterum Therapeutics plc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Iterum Therapeutics plc go public?
Iterum Therapeutics plc (ITRM) completed its IPO in 2018.What are analysts saying about ITRM?
Across the last 2 analyst actions on Iterum Therapeutics plc, there were 1 upgrade and 1 downgrade. The most recent action was from Gabelli & Co.: Hold on 2021-07-27.What companies are similar to ITRM?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ITRM side-by-side with any of them on Quantisnow.How can I track ITRM on Quantisnow?
Quantisnow aggregates Iterum Therapeutics plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ITRM to receive live email and push alerts on every new disclosure.